摘要
目的 评价2型糖尿病患者经罗格列酮长期治疗后颈动脉内膜中层厚度(IMT)的变化及机制。方法选择59例2型糖尿病伴肥胖患者,随机分成对照组(29例)与治疗组(30例),治疗组加用罗格列酮治疗24个月,治疗前后应用高频超声检测IMT及基质金属蛋白酶-9(MMP-9)、C-反应蛋白(CRP)的变化。结果与对照组比较,治疗组IMT降低(P〈0.05),治疗组治疗后血清MMP-9与CRP分别为(253.4±97.5)ng/L和(1.15±0.96)mg/L,对照组分别为(361.8±101.7)ng/L和(2.18±2.01)mg/L,两组比较差异有统计学意义(P〈0.01)。结论罗格列酮能延缓2型糖尿病患者颈动脉粥样硬化的进展,其作用机制可能通过改善MMP-9和CRP而实现。
Objective To investigate the effects and mechanism of rosiglitazone on carotid intima-media thickness (IMT) in patients with type 2 diabetes mellitus (DM) by carotid ultrasonography. Methods Fifty-nine patients with obese DM were divided into two groups randomly: patients in control group (n = 29) received routine therapy, and patients in treatment group( n = 30) received resiglitazone with routine therapy for 24 months. Carotid IMT was measured by carotid ultrasonography pre-and post-therapy. The level of ma-trix metalloproteinase-9 (MMP-9) and C-reactive protein(CRP) were assayed. Results Compared with control group, the IMT was decreased following rosiglitazone therapy ( P 〈 0. 05 ). The concentrations of MMP-9 and CRP in patients in the treatment group were (253.4±97. 5 )ng/L and( 1.15 ± 0.96)mg/L, and those in the control group were (361.8 ±101.7 )ng/L and (2. 18 ±2. 01 )mg/L, which were significantly improved. Conclusion Rosiglitazone could retard atherosclerosis progression in obese patients with type 2 DM which was achieved through improving MMP-9 and CRP.
出处
《中国基层医药》
CAS
2009年第3期447-448,共2页
Chinese Journal of Primary Medicine and Pharmacy